Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q2 FY24 results · Jul–Sep 2023
Sun Pharma Advanced Research Company reported revenue from operations of ₹21.18 crore and net loss of ₹86.42 crore for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 21.18 | — | — | — | — |
| Other income | 8.49 | — | — | — | — |
| Total income | 29.67 | — | — | — | — |
| Profit before tax | (86.42) | — | — | — | — |
| Net profit for the period | (86.42) | — | — | — | — |
| EPS, basic (₹) | (2.66) | — | — | — | — |
| Net margin (%) | -408.0 | — | — |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 21.18 | 31.54 | −32.8% | 23.95 | −11.6% |
| Other income | 8.49 | 0.06 | 142x | 10.19 | −16.7% |
| Total income | 29.67 | 31.60 | −6.1% | 34.14 | −13.1% |
| Profit before tax | (86.42) | (68.40) | Loss widened | (95.35) | Loss narrowed |
| Net profit for the period | (86.42) | (68.40) | Loss widened | (95.35) | Loss narrowed |
| EPS, basic (₹) | (2.66) | (2.52) | not comparable | (2.94) | Loss narrowed |
| Net margin (%) | -408.0 | -216.9 | -398.1 |
Consolidated
- Filed with BSE
- 07 Nov 2023, 13:06 IST
- Board meeting
- 06 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Nov 2023, 13:06 IST
- Board meeting
- 06 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE